AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35854360 — intervention group
Group type: COMPARATOR
Intervention: Intravenous therapy
Number of subjects: 720
Study 33950373 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A (BTXA) with Zinc supplementation
Number of subjects: 25
Study 33950373 — intervention group
Group type: COMPARATOR
Intervention: Botulinum Toxin A (BTXA)
Number of subjects: 25
Study 32334592 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily exenatide
Number of subjects: 66
Study 32334592 — intervention group
Group type: COMPARATOR
Intervention: Insulin (aspartate 70/30)
Number of subjects: 66
Study 36282119 — intervention group
Group type: EXPERIMENTAL
Intervention: Median Cut Hemifield Test (MCHT) using HTC Vive Pro Eye VR headset
Number of subjects: 0
Study 36282119 — intervention group
Group type: COMPARATOR
Intervention: Humphrey Visual Field Analyzer (HVFA)
Number of subjects: 0
Study 36282119 — intervention group
Group type: COMPARATOR
Intervention: Patient satisfaction with VR vision testing
Number of subjects: 0
Study 34070377 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions (nutritional management, physical activity, stress management, cognitive function improvement) for 8 weeks
Number of subjects: 63
Study 33357505 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily for 12 weeks
Number of subjects: 120
Study 33357505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 35348111 — intervention group
Group type: EXPERIMENTAL
Intervention: SB12 (300 mg dose via intravenous infusion)
Number of subjects: 0
Study 35348111 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab (RP, 300 mg dose via intravenous infusion)
Number of subjects: 0
Study 35348111 — intervention group
Group type: EXPERIMENTAL
Intervention: SB12 and Eculizumab (RP)
Number of subjects: 0
Study 32918474 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Early Intervention Service (EIS)
Number of subjects: 220
Study 32918474 — intervention group
Group type: COMPARATOR
Intervention: Regular Care (RC)
Number of subjects: 220
Study 32652987 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured home-based interview with a chronically ill patient
Number of subjects: 317
Study 32652987 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 317
Study 35040072 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Pilates Exercises (MPE)
Number of subjects: 18
Study 35040072 — intervention group
Group type: COMPARATOR
Intervention: Neurodevelopmental Therapy (NDT)
Number of subjects: 18
Study 34661623 — intervention group
Group type: EXPERIMENTAL
Intervention: Video training
Number of subjects: 0
Study 34661623 — intervention group
Group type: COMPARATOR
Intervention: Still image training
Number of subjects: 0
Study 32948057 — intervention group
Group type: EXPERIMENTAL
Intervention: multi-DNA damage response interference (mDDRi) as maintenance therapy
Number of subjects: 0
Study 32948057 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRINOX treatment
Number of subjects: 0
Study 34039583 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strategy intervention including centralised technical assistance, ongoing consultation, principal's mandated change, identifying and preparing school champions, development of implementation plans, educational outreach visits and provision of educational materials.
Number of subjects: 61
Study 34039583 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-strategy intervention
Number of subjects: 61
Study 34039583 — intervention group
Group type: COMPARATOR
Intervention: Usual support (guidelines for policy development via education department website and telephone support)
Number of subjects: 61
Study 32814158 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase group
Number of subjects: 73
Study 32814158 — intervention group
Group type: COMPARATOR
Intervention: Luteal phase group
Number of subjects: 73
Study 32500650 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (SA), N = 32,000, PSA screening at 4-year intervals until 2007.
Number of subjects: 5128
Study 32500650 — intervention group
Group type: COMPARATOR
Intervention: Control arm (CA), N = 48,458, no PSA screening.
Number of subjects: 5128
Study 32500650 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic HRQOL scores
Number of subjects: 5128
Study 34921796 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-Shared Care (TSC)
Number of subjects: 324
Study 34921796 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Specialist Mental Health Care (PSY)
Number of subjects: 324
Study 33227037 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-enhanced ultrasonography training program
Number of subjects: 101
Study 35666542 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Balance Board System (WBBS)
Number of subjects: 90
Study 35666542 — intervention group
Group type: COMPARATOR
Intervention: Foam Posturography System (FPS)
Number of subjects: 90
Study 33233945 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses
Number of subjects: 83
Study 33233945 — intervention group
Group type: COMPARATOR
Intervention: Placebo insoles
Number of subjects: 83
Study 32004775 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) using a new HPLC-MS/MS method for quantifying dolutegravir (DTG), elvitegravir (ELV), rilpivirine (RPV), raltegravir (RAL), raltegravir‐Î²‐D‐glucuronide (RAL‐GLU), darunavir (DRV), and ritonavir (RTV) in human plasma.
Number of subjects: 0
Study 35395206 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0
Study 35395206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33923171 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g of mixed soluble and insoluble fiber for 8 weeks
Number of subjects: 14
Study 32694162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric Citrate (2 g three times a day with meals, n=30)
Number of subjects: 60
Study 32694162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric Citrate
Number of subjects: 60
Study 32694162 — intervention group
Group type: COMPARATOR
Intervention: Ferrous Sulfate (325 mg three times a day, n=30)
Number of subjects: 60
Study 35507383 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of dexamethasone (0.6 mg/kg per dose, maximum of 16 mg)
Number of subjects: 308
Study 35507383 — intervention group
Group type: COMPARATOR
Intervention: 2 doses of dexamethasone (0.6 mg/kg per dose, maximum of 16 mg)
Number of subjects: 308
Study 35507383 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of dexamethasone
Number of subjects: 308
Study 35507383 — intervention group
Group type: COMPARATOR
Intervention: 2 doses of dexamethasone
Number of subjects: 308
Study 32170358 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon-defined assessment (SDA) at 10°
Number of subjects: 250
Study 32170358 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon-defined assessment (SDA) at 45°
Number of subjects: 250
Study 32170358 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon-defined assessment (SDA) at 90°
Number of subjects: 250
Study 33406241 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterpipe tobacco packaging with modified risk tobacco product (MRTP) claims
Number of subjects: 10
Study 33406241 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterpipe tobacco packaging with descriptors implying reduced harm
Number of subjects: 10
Study 33406241 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterpipe tobacco packaging with text-only warnings
Number of subjects: 10
Study 33406241 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterpipe tobacco packaging with imagery
Number of subjects: 10
Study 33406241 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterpipe tobacco packaging marketing appeals
Number of subjects: 10
Study 36116229 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + FIBROWALK
Number of subjects: 330
Study 36116229 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + MPP
Number of subjects: 330
Study 36116229 — intervention group
Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 330
Study 33779288 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Kinetic Enucleation of the Prostate (PKEP)
Number of subjects: 160
Study 33779288 — intervention group
Group type: COMPARATOR
Intervention: Holmium Laser Enucleation of the Prostate (HoLEP)
Number of subjects: 160
Study 33779288 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PKEP and HoLEP
Number of subjects: 160
Study 33779288 — intervention group
Group type: COMPARATOR
Intervention: HoLEP
Number of subjects: 160
Study 32903201 — intervention group
Group type: EXPERIMENTAL
Intervention: WOC nurse interventions (67.5% of patients treated by WOC nurse)
Number of subjects: 572
Study 35027161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy for Suicide Prevention (CTSP) + Treatment as Usual (TAU)
Number of subjects: 150
Study 35027161 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 150
Study 32853559 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone plus misoprostol
Number of subjects: 711
Study 32853559 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus misoprostol
Number of subjects: 711
Study 35114151 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab-containing therapy (with CHOP chemotherapy)
Number of subjects: 1068
Study 35114151 — intervention group
Group type: COMPARATOR
Intervention: CHOP chemotherapy only
Number of subjects: 1068
Study 35114151 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab therapy (in CLL8 trial)
Number of subjects: 1068
Study 35114151 — intervention group
Group type: COMPARATOR
Intervention: FC chemotherapy only
Number of subjects: 1068
Study 32939934 — intervention group
Group type: EXPERIMENTAL
Intervention: Static CAIS (n = 30)
Number of subjects: 30
Study 32939934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic CAIS (n = 30)
Number of subjects: 30
Study 32463599 — intervention group
Group type: EXPERIMENTAL
Intervention: HS016
Number of subjects: 136
Study 34299697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) as an adjunctive to treatment-as-usual (TAU)
Number of subjects: 177
Study 34299697 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 177
Study 32469095 — intervention group
Group type: EXPERIMENTAL
Intervention: Sponsor-provided drugs
Number of subjects: 345
Study 32469095 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry-sponsored trials
Number of subjects: 345
Study 32469095 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic trials
Number of subjects: 345
Study 34647777 — intervention group
Group type: EXPERIMENTAL
Intervention: Path2Quit
Number of subjects: 119
Study 34647777 — intervention group
Group type: COMPARATOR
Intervention: NCI's SmokefreeTXT
Number of subjects: 119
Study 32385058 — intervention group
Group type: EXPERIMENTAL
Intervention: Home cook intervention package including community-based standardized offline and online health education and salt intake monitoring for 1 year
Number of subjects: 1560
Study 32385058 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1560
Study 33646918 — intervention group
Group type: EXPERIMENTAL
Intervention: Good sleep condition
Number of subjects: 0
Study 33646918 — intervention group
Group type: COMPARATOR
Intervention: Poor sleep condition
Number of subjects: 0
Study 33470660 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral Biportal Endoscopy (UBE)
Number of subjects: 154
Study 33470660 — intervention group
Group type: COMPARATOR
Intervention: Tubular Microendoscopy (TME)
Number of subjects: 154
Study 32736928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin C (40 mg/40 ml) three times a week for 2 weeks
Number of subjects: 120
Study 32736928 — intervention group
Group type: COMPARATOR
Intervention: TURBT and six weekly adjuvant instillations
Number of subjects: 120
Study 32736928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin C
Number of subjects: 120
Study 36274158 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg progesterone daily for 4 days of abstinence
Number of subjects: 39
Study 34061838 — intervention group
Group type: EXPERIMENTAL
Intervention: GMZ2 vaccine adjuvanted with Cationic Adjuvant Formulation (CAF) 01
Number of subjects: 50
Study 34061838 — intervention group
Group type: EXPERIMENTAL
Intervention: GMZ2 vaccine adjuvanted with Alhydrogel
Number of subjects: 50
Study 34061838 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine (Rabies)
Number of subjects: 50
Study 34061838 — intervention group
Group type: EXPERIMENTAL
Intervention: Helminth infection (mono-infection)
Number of subjects: 50
Study 34061838 — intervention group
Group type: EXPERIMENTAL
Intervention: Helminth infection (co-infection)
Number of subjects: 50
Study 34061838 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of helminth infection
Number of subjects: 50
Study 35932186 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Activity Program (TAP)
Number of subjects: 235
Study 35932186 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 235
Study 32635612 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA)
Number of subjects: 90
Study 32635612 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidonic acid (AA)
Number of subjects: 90
Study 32635612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood DHA
Number of subjects: 90
Study 32635612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood AA
Number of subjects: 90
Study 32635612 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA and AA levels
Number of subjects: 90
Study 35725347 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media intervention group (including VCT services and comprehensive strategies through social media)
Number of subjects: 315
Study 35725347 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine voluntary counseling and testing services)
Number of subjects: 315
Study 34167881 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination supplementation with vitamin B12 and folate
Number of subjects: 0
Study 34167881 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and supplemental thiamine intake
Number of subjects: 0
Study 34167881 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine levels
Number of subjects: 0
Study 34167881 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular screening protocols
Number of subjects: 0
Study 34557922 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT) with proctored practice
Number of subjects: 198
Study 34557922 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT) with unproctored practice
Number of subjects: 198
Study 34557922 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 198
Study 34557922 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness practice (frequency of 3 or more days per week)
Number of subjects: 198
Study 34557922 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness practice (frequency of practice)
Number of subjects: 198
Study 32858239 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvalent mechanical bacterial lysates (PMBLs)
Number of subjects: 70
Study 32858239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 32608179 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual experience intervention before the scan
Number of subjects: 200
Study 32608179 — intervention group
Group type: COMPARATOR
Intervention: Control group (no virtual experience)
Number of subjects: 200
Study 35122992 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of trans-resveratrol per day for four weeks
Number of subjects: 20
Study 35122992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg wheat flour) for four weeks
Number of subjects: 20
Study 33587894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib (COMBI-d)
Number of subjects: 423
Study 33587894 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib (COMBI-MB)
Number of subjects: 423
Study 33587894 — intervention group
Group type: COMPARATOR
Intervention: Dabrafenib plus placebo (COMBI-d)
Number of subjects: 423
Study 33151315 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE plus ablative therapy (stereotactic body radiation therapy, microwave ablation, radiofrequency ablation)
Number of subjects: 289
Study 33151315 — intervention group
Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 289
Study 33151315 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE plus ablative therapy
Number of subjects: 289
Study 34481561 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 34481561 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 35296398 — intervention group
Group type: EXPERIMENTAL
Intervention: NU-FlexSIV Socket
Number of subjects: 30
Study 35296398 — intervention group
Group type: COMPARATOR
Intervention: Ischial Containment (IC) Socket
Number of subjects: 30
Study 33503527 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodized exercise training (MSPER)
Number of subjects: 31
Study 33503527 — intervention group
Group type: COMPARATOR
Intervention: Classic endurance training (MSCLA)
Number of subjects: 31
Study 35564687 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused-Attention Meditation (FAM) training for 8 weeks
Number of subjects: 140
Study 35564687 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list, no intervention)
Number of subjects: 140
Study 611775172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal local anesthetic (20 mL 0.25% or 0.125% bupivacaine)
Number of subjects: 184
Study 611775172 — intervention group
Group type: COMPARATOR
Intervention: Control (20 mL 0.9% NaCl)
Number of subjects: 184
Study 35724745 — intervention group
Group type: EXPERIMENTAL
Intervention: Itrīfal Shāhtra (oral) and Marham Ḥina (topical)
Number of subjects: 66
Study 35724745 — intervention group
Group type: COMPARATOR
Intervention: PUVAsol (oral) and petrolatum (topical)
Number of subjects: 66
Study 35724745 — intervention group
Group type: EXPERIMENTAL
Intervention: Itrīfal Shāhtra and Marham Ḥina
Number of subjects: 66
Study 34153715 — intervention group
Group type: EXPERIMENTAL
Intervention: lapatinib-trastuzumab
Number of subjects: 121
Study 34153715 — intervention group
Group type: EXPERIMENTAL
Intervention: pCR
Number of subjects: 121
Study 34153715 — intervention group
Group type: EXPERIMENTAL
Intervention: TILs
Number of subjects: 121
Study 34153715 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminal-A subtype
Number of subjects: 121
Study 34082392 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle energy techniques (METs) combined with Swedish massage
Number of subjects: 40
Study 34082392 — intervention group
Group type: COMPARATOR
Intervention: Swedish massage alone
Number of subjects: 40
Study 32416008 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment arms from CARE-HD
Number of subjects: 0
Study 32416008 — intervention group
Group type: COMPARATOR
Intervention: Placebo data from CARE-HD
Number of subjects: 0
Study 32416008 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease burden score (a product of age and expanded CAG length)
Number of subjects: 0
Study 34568050 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine manipulator (arm B)
Number of subjects: 154
Study 34568050 — intervention group
Group type: COMPARATOR
Intervention: No uterine manipulator (arm A)
Number of subjects: 154
Study 33197570 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind Sound Resonance Technique (MSRT)
Number of subjects: 60
Study 33197570 — intervention group
Group type: COMPARATOR
Intervention: Supine Rest (SR)
Number of subjects: 60
Study 33261633 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocryostimulation (NCS)
Number of subjects: 41
Study 33261633 — intervention group
Group type: COMPARATOR
Intervention: Traditional ice application
Number of subjects: 41
Study 36476502 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldilocks Work intervention (GoldiCare)
Number of subjects: 11
Study 36476502 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal work schedule)
Number of subjects: 11
Study 33571946 — intervention group
Group type: EXPERIMENTAL
Intervention: sc IFN β‐1a (22 or 44 μg, three-times-weekly)
Number of subjects: 367
Study 32150701 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling garment infused with 18 °C water during exercise sessions.
Number of subjects: 12
Study 32150701 — intervention group
Group type: COMPARATOR
Intervention: Control (no cooling) during exercise sessions.
Number of subjects: 12
Study 33687748 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla‐300)
Number of subjects: 596
Study 33687748 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec 100 U/mL (IDeg‐100)
Number of subjects: 596
Study 33378433 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections with CaCl2 activating solution
Number of subjects: 16
Study 33378433 — intervention group
Group type: COMPARATOR
Intervention: CaCl2 injection only (control)
Number of subjects: 16
Study 33378433 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PRP and CaCl2 injections
Number of subjects: 16
Study 34864554 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-delivered mHealth intervention targeting adolescent depression and anxiety
Number of subjects: 0
Study 33709271 — intervention group
Group type: EXPERIMENTAL
Intervention: PRG with gastropexy
Number of subjects: 60
Study 33709271 — intervention group
Group type: COMPARATOR
Intervention: PRG without gastropexy
Number of subjects: 60
Study 32334332 — intervention group
Group type: EXPERIMENTAL
Intervention: Active a-tDCS (1 mA, 20 min, for five consecutive days)
Number of subjects: 32
Study 32334332 — intervention group
Group type: EXPERIMENTAL
Intervention: Active a-tDCS
Number of subjects: 32
Study 32334332 — intervention group
Group type: COMPARATOR
Intervention: Sham a-tDCS
Number of subjects: 32
Study 35511454 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) + RT + TMZ
Number of subjects: 716
Study 35511454 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) + RT + TMZ
Number of subjects: 716
Study 34520538 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable bulk-fill and microhybrid resin composites (XST)
Number of subjects: 53